Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Efficacy of AST-120 in dogs with chronic idiopathic enteropathies (2013)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Volkmann, M (WE 20)
    Wirtherle, N C
    Beddies, G F
    Kohn, B (WE 20)
    Quelle
    Journal of veterinary internal medicine; 27(6) — S. 1637–1641
    ISSN: 0891-6640
    Sprache
    Englisch
    Verweise
    DOI: 10.1111/jvim.12212
    Pubmed: 24128298
    Kontakt
    Klinik für kleine Haustiere

    Oertzenweg 19 b
    Haus 1
    14163 Berlin
    +49 30 838 62356
    kleintierklinik@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    Chronic idiopathic enteropathies (CIE) in dogs are complex diseases of unknown origin. AST-120 is a spherical carbon adsorbent preparation with a high adsorption ability for low molecular substances.

    Evaluation of the clinical efficacy of AST-120 in dogs with CIE.

    Ten client-owned dogs with mild (n = 7) to moderate (n = 3) CIE.

    Explorative, prospective, randomized, placebo-controlled, double-blinded pilot study. Dogs with chronic diarrhea and no or insufficient response to an elimination diet were included. The dogs received either AST-120 (n = 5) or placebo (n = 5) for a duration of 21 days. The canine inflammatory bowel disease activity index (CIBDAI) was used to assess disease severity at baseline and clinical outcome after 3 weeks of treatment. Furthermore, changes in body weight and the parameters stool consistency and frequency were compared within and between groups.

    The mean CIBDAI score decreased from 5.6 (SD 1.5) to 2.0 (SD 1.2) in the AST-120 group (P = .125) and from 4.8 (SD .8) to 3.6 (SD 2.3) in the placebo group (P = .688). Compared with baseline, posttreatment CIBDAI scores decreased more than 60% in 4/5 dogs treated with AST-120 and in 1/5 dogs treated with placebo (P = .206). Changes in CIBDAI scores, body weights, stool consistency, and frequency within and between groups did not achieve statistical significance after 3 weeks of treatment. No adverse effects of AST-120 were noted.

    This study investigated potential efficacy of AST-120 as an alternative therapy in dogs with mild-to-moderate CIE.